Saluda Medical Welcomes Barry Regan as New CEO
Saluda Medical, a leader in neuromodulation, has recently appointed Barry Regan as their new Chief Executive Officer. Regan's extensive experience will play a pivotal role in guiding the company's mission to innovate treatments for chronic neurological conditions. This leadership change follows the addition of other key executives, further strengthening the company's management team.
Strengthening Leadership with Key Appointments
The announcement of Barry Regan's appointment comes on the heels of Saluda's recent recruitment of Mike Mathias as Chief Commercial Officer and Jim Erickson as Chief Financial Officer. These strategic appointments are expected to significantly enhance the capabilities and direction of Saluda Medical.
Doug Godshall, Chairman of the Board of Directors, expressed enthusiasm about Regan's arrival, noting that his background and expertise are invaluable at this stage of the company’s development. Godshall believes that with the right leadership team, Saluda is well-positioned to revolutionize the field of spinal cord stimulation.
Barry Regan's Extensive Experience
Barry Regan brings over three decades of operations experience in both the medical device and pharmaceutical fields. Before joining Saluda Medical, he held the position of Executive Vice President, Global Operations at Dexcom, where he oversaw significant initiatives related to production and capital investments. His prior leadership at Wright Medical as Senior Vice President Global Operations further establishes his capacity to manage operations at a high level.
In his own words, Regan stated, "I am thrilled to join Saluda as Chief Executive Officer at this exciting time... I look forward to working with the entire team to continue establishing Saluda as a new standard of care in neuromodulation." His excitement reflects the innovative advancements Saluda Medical aims to achieve under his leadership.
About Saluda Medical
Saluda Medical focuses on developing transformative treatments for chronic neurological conditions through its novel neuromodulation platform. Unlike traditional methods, their closed-loop dose-control platform adjusts therapy in real-time by measuring neural responses, optimizing patient care significantly. The flagship Evoke System exemplifies this innovation, assisting in the management of chronic pain conditions while enhancing patients’ quality of life.
Commitment to Innovation
The Evoke System has garnered attention for demonstrating superior effectiveness in managing chronic pain compared to conventional open-loop therapies. Clinical studies have showcased impressive long-term outcomes, affirming Saluda’s commitment to providing leading-edge treatments for patients suffering from debilitating pain.
As the company continues to grow, the focus remains on expanding the capabilities of their neuromodulation solutions, influencing the future of pain management with scientific rigor and a patient-centered approach.
Frequently Asked Questions
1. What is the main focus of Saluda Medical?
Saluda Medical is focused on the development of innovative treatments for chronic neurological conditions through neuromodulation technology.
2. Who is the new CEO of Saluda Medical?
The new CEO of Saluda Medical is Barry Regan, who has extensive experience in the medical device industry.
3. What is the Evoke System?
The Evoke System is Saluda's flagship product, designed to manage chronic pain by utilizing a closed-loop, dose-control method for spinal cord stimulation.
4. What experience does Barry Regan bring to Saluda Medical?
Barry Regan has over 30 years of experience in operations, including leadership roles at Dexcom and Wright Medical.
5. How does the Evoke System benefit patients?
The Evoke System benefits patients by providing personalized pain management through real-time adjustments to stimulation, improving outcomes and minimizing discomfort.
